A predictive biophysical model that integrates protein-DNA structures and sequences to accurately determine genomic binding sites and affinities of DNA-binding proteins.

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Find the latest institutional holdings data for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) including shareholders, ownership summaries, and holding activities at Nasdaq.com.

View the most recent data and latest information on option chains for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.